Arsanis Out-Licenses Preclinical Stage E. coli Monoclonal Antibodies
- Category: More News
- Published on Thursday, 05 April 2018 09:53
- Hits: 912
Transaction provides potential for further development of novel mAbs while allowing Arsanis to continue to focus its resources on ongoing Phase 2 clinical trial of lead product candidate ASN100
WALTHAM, MA, USA & VIENNA, Austria I April 04, 2018 I Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced that it has entered into an agreement under which BB100, LLC has secured an exclusive, worldwide preclinical development license, and an option to a clinical development and commercialization license, to monoclonal antibodies (mAbs) targeting E. coli that were discovered by Arsanis in its ASN200 program.
“This transaction allows Arsanis to continue the focused execution of our ongoing ASN100 Phase 2 clinical trial while providing for the potential advancement of our novel, multi-modal mAbs targeting E. coli, a leading cause of serious hospital infections,” said René Russo, chief executive officer of Arsanis. “We are pleased to place these mAbs in the hands of BB100, a subsidiary of Bravos Bioscience, LLC, led by Dr. Paul Ambrose and a leadership team that is globally recognized as a leader in anti-infective drug development and has played a critical role in the development and approval of many anti-infectives developed over the last decade.”
Under the agreement, Arsanis has granted BB100 the exclusive right to conduct further preclinical development activities on licensed mAbs, with an option to enter into an exclusive global development and commercial license.
The ASN200 program is currently in preclinical development. Within this program, Arsanis discovered a unique monoclonal antibody, ASN-4, that has multiple modes of action against the hyper-virulent, multi-drug resistant E. coli ST131-O25b:H4 clone. ASN-4 is directly bactericidal and provides anti-inflammatory effects without the need for innate immune cells and therefore, has the potential to be beneficial even in immunocompromised patients. In addition, ASN-4 has been demonstrated to potentiate the activity of antibiotics, potentially minimizing the use of last-line antibiotics with less favorable toxicity profiles. ASN-4 is highly potent and elicits a high level of protection at very low doses in relevant animal models and therefore has the potential to be used both for prevention of disease in colonized, high-risk patients and treatment of patients with serious infections, including those in whom antibiotics have failed.
BB100 is a fully owned subsidiary of Bravos Biosciences, LLC. Paul G. Ambrose, Pharm.D., F.I.D.S.A., currently serves as president of the Institute for Clinical Pharmacodynamics (ICPD, Schenectady, NY). Both Bravos Biosciences and ICPD are cofounded by Drs. Ambrose, Sujata M. Bhavnani and Christopher M. Rubino. The team’s areas of scientific inquiry primarily involve anti-infective translational science, with the goal of improving patient care through the application of pharmacokinetic-pharmacodynamic (PK-PD) principles. Dr. Ambrose has held academic appointments at the University of Oxford and the University at Buffalo as well as past industry positions including at Bristol Myers Squibb. Dr. Ambrose holds a Pharm.D. from the University of the Pacific and completed a Post-Doctoral Fellowship in infectious diseases at Hartford Hospital.
Arsanis, Inc. is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to what the company believes to be some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to further its goal of building and advancing a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets. The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in a Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.
Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).